Radiotherapy and Clinical Oncology最新文献

Most Appropriate Radiation Therapy Techniques for The Breast Cancer Treatment: Dosimetric Analysis of Three Different Radiation Therapy Methods 最适合乳腺癌治疗的放射治疗技术:三种不同放射治疗方法的剂量学分析

Radiotherapy and Clinical Oncology Pub Date : 2023-06-19 DOI: 10.31487/j.rco.2023.01.01

Kristina Tumanova, S. Nidal, A. Popodko, A. Stolbovoy

引用次数: 0

Immunotherapy, Immunobiomarkers and Gene Analysis Role in the Improvement of Lung Cancer Treatment 免疫疗法、免疫生物标志物和基因分析在改善肺癌治疗中的作用

Radiotherapy and Clinical Oncology Pub Date : 2022-12-15 DOI: 10.31487/j.rco.2022.01.01

M. Wael, Mostafa Hosam, A. Youssef, Rawan Ellackany, Abdelrahman Alzahabi

{"title":"Immunotherapy, Immunobiomarkers and Gene Analysis Role in the Improvement of Lung Cancer Treatment","authors":"M. Wael, Mostafa Hosam, A. Youssef, Rawan Ellackany, Abdelrahman Alzahabi","doi":"10.31487/j.rco.2022.01.01","DOIUrl":"https://doi.org/10.31487/j.rco.2022.01.01","url":null,"abstract":"Lung cancer is the second most common cancer with a poor survival rate (18.6%). Recently treatment of lung cancer has been improved starting from choosing appropriate treatment by gene and immunobiomarkers analysis to immunotherapy which played a major role in the treatment of lung cancer and showed improvement in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) with less adverse effects. Through this triad Immunotherapy, immunobiomarkers and Gene analysis oncologists can provide better treatment for lung cancer patients.\u0000The most important cause that makes immunotherapy shows good results in the treatment of lung cancer is P53 gene mutation which is present in more than half of lung cancer patients. P53 gene mutation causes high genetic instability so causes more mutations in cancer cells and more neoantigens are formed. These neoantigens make cancer cells more immunogenic and respond better to the treatment of lung cancer by immunotherapy.\u0000The most common immunotherapy drug family that is effective in the treatment of lung cancer is Immune checkpoint inhibitors. Throughout the journey of treatment Immune checkpoint inhibitors can develop resistance by multiple mechanisms that are discussed in the review and to overcome these mechanisms Immune checkpoint inhibitors can be used in combination with other immunotherapies or radiotherapy.","PeriodicalId":336576,"journal":{"name":"Radiotherapy and Clinical Oncology","volume":"376 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131629269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early Detection of Response to Radiotherapy Treatment with 11C-Acetate PET Imaging 11C-Acetate PET显像早期检测放疗反应

Radiotherapy and Clinical Oncology Pub Date : 2021-08-09 DOI: 10.31487/j.rco.2021.01.03

M. Bentourkia, Redha-alla Abdo, Chang-Shu Wang, É. Lavallée, F. Lessard

{"title":"Early Detection of Response to Radiotherapy Treatment with 11C-Acetate PET Imaging","authors":"M. Bentourkia, Redha-alla Abdo, Chang-Shu Wang, É. Lavallée, F. Lessard","doi":"10.31487/j.rco.2021.01.03","DOIUrl":"https://doi.org/10.31487/j.rco.2021.01.03","url":null,"abstract":"11C-Acetate radiotracer with Positron Emission Tomography (PET) imaging is currently used in cardiovascular imaging for perfusion and oxygen consumption measurement. It is also used, among other diseases, for prostate cancer as this radiotracer does not accumulate in the bladder. The present study reports the assessment of the radiotherapy treatment by measuring the tumor perfusion and oxygenation before and at mid-treatment by imaging with dynamic 11C-Acetate in patients with head and neck cancer. A pre-treatment dynamic 11C-Acetate and a clinical static 18F-FDG PET were conducted before initiation of the treatment, and the second 11C-Acetate dynamic scan was performed after four weeks of radiotherapy (i.e., after a dose of 35 Gy for a total of 70 Gy). The two-tissue compartment model was applied to 11C-Acetate images to extract the perfusion and oxygen consumption. The results showed a reduction in tumor volume by more than 50% compared to the initial volume in patient-1. Besides, patient-2 has displayed a more reduced tumor volume after 4 weeks of treatment. The 11C-Acetate rate constant k2 representing oxygen consumption increased after radiotherapy dose in both patients. This increase of k2 could reflect the reoxygenation process inside the tumor, and it can reflect the early treatment response. In conclusion, 11C-Acetate could predict the early changes in the tumor perfusion and the oxidative metabolism to optimally adjust the treatment.","PeriodicalId":336576,"journal":{"name":"Radiotherapy and Clinical Oncology","volume":"31 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126751168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tumor-Infiltrantig Lymphocytes Density as Determinant in Early Stage Colorectal Cancer Prognosis: A Single Centre Pilot Study 肿瘤浸润淋巴细胞密度是早期结直肠癌预后的决定因素:一项单中心试点研究

Radiotherapy and Clinical Oncology Pub Date : 2019-10-18 DOI: 10.31487/j.rco.2019.01.02

C. L. Nigro, C. Granetto, D. Vivenza, E. Fea, M. Merlano, M. Fortunato, T. Fabozzi, V. Ricci

{"title":"Tumor-Infiltrantig Lymphocytes Density as Determinant in Early Stage Colorectal Cancer Prognosis: A Single Centre Pilot Study","authors":"C. L. Nigro, C. Granetto, D. Vivenza, E. Fea, M. Merlano, M. Fortunato, T. Fabozzi, V. Ricci","doi":"10.31487/j.rco.2019.01.02","DOIUrl":"https://doi.org/10.31487/j.rco.2019.01.02","url":null,"abstract":"Stage II colon cancer (CC) is a heterogeneous disease with different clinical behaviour. There is a high degree of uncertainty in recommending adjuvant chemotherapy, which is usually suggested in the high-risk population on the basis of TNM, stage and key biological markers. Published data suggest that specific tumor-infiltrating lymphocytes (S-TILs) (CD3+, CD8+, CD45RO+) may represent a valuable prognostic tool to drive the decision-making process.\u0000We performed an analysis on 13 cases of stage II and III CC that relapsed, and on 15 cases that did not. We analyzed the density of CD3+, CD8+ and CD45RO+ in the surgical samples after radical surgery by IHC in the center of the tumor (CT) and in its invasive margin (IM). For each marker, we identified two grading of staining, high density (HD) or low density (LD), where the cut-off was the median value observed. This analysis was carried out stratifying patients in two cohorts: stage II (12 patients) and stage III (16 patients).\u0000Density of CD3+, CD8+ and CD45RO+ in CT did not affect DFS and OS, except for OS in stage II pts for CD3+ (P=0.012).\u0000Conversely HD of CD3+, CD8+ and CD45RO+ in IM showed significant benefit in DFS compared to LD (P=0.001, P=0.013 and P=0.001 respectively) in stage II patients and, only for CD3+, also in stage III patients (P=0.048). Similarly, we observed a significant gain in OS in pts with HD CD3+ and CD45RO+ (P=0.05 and P=0.003) but not CD8+ (P=0.25) in IM for stage II patients.\u0000S-TILs might represent a valuable prognostic tool to drive the decision-making process especially for stage II CC disease, with a more pronounced role of S-TILs in IM compared to CT. Our results will be verified in ongoing large prospective study.","PeriodicalId":336576,"journal":{"name":"Radiotherapy and Clinical Oncology","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126772848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0